China Reforms Welcome, But More Needed: Frazier
This article was originally published in PharmAsia News
Visiting Beijing on another grey day choked with thick smog, PhRMA chairman Kenneth Frazier stressed the need for drug companies to adopt flexible pricing practices in the Chinese market, along with reimbursement and other measures to support innovation, and a globally-harmonized, science-based, transparent and predictable regulatory framework.
You may also be interested in...
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.